Document resource
Introduction The current treatment landscape for patients with refractory generalised myasthenia gravis (gMG) in England includes chronic intravenous immunoglobulin (IVIg) and plasma exchange (PLEX). These are primarily hospital based treatments, making them resource intensive. Zilucoplan, a daily self-administered injection, and rozanolixizumab, a subcutaneous infusion weekly for 6 weeks, may alleviate this burden if approved by NICE. We calculated the potential reduction in staff time requirements by introducing these treatments for the refractory gMG subpopulation.Methods Staff time requirements per treatment were established following clinician interviews. Expert neurologists also informed chronic 4-weekly IVIg and PLEX dosing. An Excel® model was developed comparing administrations and staff time requirements per treatment in the current vs proposed treatment scenario.Results Assuming 50% of patients with refractory gMG receive either zilucoplan or rozanolixizumab instead of IVIg or PLEX, results indicate a reduction of 20,794 hours of consultant time, 750,893 hours of nurse time, and 86,966 hours of administrative support time in England over 5 years.Conclusion Zilucoplan and rozanolixizumab are associated with staff and patient time savings by potentially displacing time-intensive IVIg or PLEX for refractory gMG. Patients would need fewer hospital visits, and staff time requirements would be reduced for the healthcare system.april.betts@ucb.com